Eli Lilly and Company’s Stock Price Hits $923.71: Navigates a 1.21% Dip in the Market

Eli Lilly and Company (LLY)

923.71 USD -11.31 (-1.21%) Volume: 2.04M

Eli Lilly and Company’s stock price stands at 923.71 USD, experiencing a slight dip of -1.21% this trading session. Despite the recent drop, LLY’s trading volume remains robust at 2.04M. The pharmaceutical giant’s stock has displayed remarkable resilience with a year-to-date increase of +58.46%, making it a noteworthy performer in the market.

Latest developments on Eli Lilly and Company

Eli Lilly & Company has made significant strides in expanding its manufacturing capabilities with a $1.8 billion investment in Ireland, focusing on scaling up production of drugs for Alzheimer’s, obesity, and diabetes. The pharmaceutical giant also received FDA approval for its eczema drug, EBGLYSS™, further solidifying its position in the market. With positive phase 3 results for a weekly insulin formulation and a Buy rating from Citi, Eli Lilly’s stock price has seen gains as investors show confidence in the company’s growth prospects. This expansion in Ireland marks a strategic move for Eli Lilly as it continues to innovate and deliver groundbreaking solutions in the healthcare industry.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the Smartkarma Smart Scores for Eli Lilly & Company, the company seems to have a positive long-term outlook. With a high momentum score of 4, it indicates that the company is performing well in terms of stock price performance and market trends. Additionally, a growth score of 3 suggests that Eli Lilly & Company is positioned for future expansion and development. While the value, dividend, and resilience scores are not as high, the overall outlook for the company appears to be promising.

Eli Lilly & Company is a pharmaceutical company that focuses on discovering, developing, manufacturing, and selling products for both humans and animals. With a diverse range of products in areas such as neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health, the company has a strong presence in markets worldwide. The Smartkarma Smart Scores provide insight into the company’s performance in key areas, indicating a positive momentum and growth outlook for Eli Lilly & Company in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma